Investigational Drug Fails As Standalone Mesothelioma Treatment, AstraZeneca Says
(February 29, 2016, 10:38 AM EST) -- LONDON — The investigational drug Tremelimumab does not improve overall survival rates of mesothelioma patients when used alone, AstraZeneca announced Feb. 29....